ABSTRACT
BACKGROUND AND OBJECTIVE: Highly active antiretroviral therapy (HAART) has been considered to be ineffective in controlling hepatitis C viremia in the first year of treatment. The present study evaluates the effect of prolonged HAART upon HCV-VL. PATIENTS AND METHOD: We selected those cases with positive serology for HCV, never been treated with protease inhibitors (PIs) at baseline, which after the introduction of HAART maintained undetectable HIV viral loads (HIV-VL) uninterruptedly for at least three years. Determinations were made of HCV-VL at baseline and after two and three years of HIV-VL suppression. Spearman coefficient and Friedman test were used. RESULTS: Of these patients, 21 satisfied the inclusion criteria. HCV-VL remained without significant changes and with relatively stable levels throughout the three-year follow-up period. However, two patients showed HCV-VL negative conversion after two years, that persisted after three years. CONCLUSIONS: Patients who respond to HAART maintain stable HCV-VL. Some subjects may exhibit HCV RNA clearance in the first two years of treatment, maintaining this situation after three years.
Subject(s)
Antiretroviral Therapy, Highly Active , Hepacivirus/drug effects , Viral Load/statistics & numerical data , Follow-Up Studies , Humans , Time FactorsABSTRACT
FUNDAMENTO Y OBJETIVO: El tratamiento antirretroviral de gran actividad (TARGA) se ha considerado ineficaz en el control de la viremia por el virus de la hepatitis C (VHC) en el primer año de tratamiento. Se evalúa el efecto del tratamiento antirretroviral efectivo prolongado en la carga viral del VHC. PACIENTES Y MÉTODO: Se relacionó a aquellos pacientes con infección por el VIH y serología positiva para el VHC, que tras iniciar el TARGA mantenían cargas virales para el VIH indetectables durante al menos 3 años. Se determinaron las CV-VHC basalmente y a los 2 y 3 años. RESULTADOS: Veintiún pacientes cumplían los criterios de inclusión, de los que 12 eran naives y el resto habían sido tratados con mono o biterapias aunque tenían CV-VIH elevadas. La CV-VHC se mantuvo sin cambios significativos y con valores relativamente estables durante los tres años. Sin embargo, dos pacientes negativizaron la CV-VHC a los dos años, manteniéndose en el control a los tres años. CONCLUSIONES: Los pacientes que responden al TARGA mantienen cifras de CV-VHC estables, si bien algunos enfermos aclaran el ARN del VHC cuando el tratamiento se prolonga más de dos años (AU)
Subject(s)
Middle Aged , Aged, 80 and over , Aged , Male , Female , Humans , Home Care Services, Hospital-Based , Patient Readmission , Patient Discharge , Antiretroviral Therapy, Highly Active , Length of Stay , Time Factors , Hepacivirus , Viral Load , Treatment Outcome , Pulmonary Disease, Chronic Obstructive , Feasibility Studies , Follow-Up Studies , Program Evaluation , Preventive Health ServicesSubject(s)
Emigration and Immigration/statistics & numerical data , Intestines/parasitology , Parasitic Diseases/ethnology , Parasitic Diseases/parasitology , Adolescent , Adult , Animals , Catchment Area, Health , Female , Humans , Male , Middle Aged , Spain/epidemiology , Strongyloides stercoralis/isolation & purification , Strongyloidiasis/ethnology , Strongyloidiasis/parasitologyABSTRACT
No disponible
